Your browser doesn't support javascript.
loading
Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine.
Ye, Xiaohua; Shih, David J H; Ku, Zhiqiang; Hong, Junping; Barrett, Diane F; Rupp, Richard E; Zhang, Ningyan; Fu, Tong-Ming; Zheng, W Jim; An, Zhiqiang.
Afiliación
  • Ye X; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Shih DJH; Center for Infectious Disease Research, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
  • Ku Z; School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Hong J; School of Biomedical Sciences, The University of Hong Kong, Pokfulam, Hong Kong SAR.
  • Barrett DF; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Rupp RE; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Zhang N; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
  • Fu TM; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
  • Zheng WJ; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
  • An Z; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
NPJ Vaccines ; 9(1): 70, 2024 Apr 01.
Article en En | MEDLINE | ID: mdl-38561339
ABSTRACT
Human cytomegalovirus (HCMV) is a leading infectious cause of birth defects and the most common opportunistic infection that causes life-threatening diseases post-transplantation; however, an effective vaccine remains elusive. V160 is a live-attenuated replication defective HCMV vaccine that showed a 42.4% efficacy against primary HCMV infection among seronegative women in a phase 2b clinical trial. Here, we integrated the multicolor flow cytometry, longitudinal T cell receptor (TCR) sequencing, and single-cell RNA/TCR sequencing approaches to characterize the magnitude, phenotype, and functional quality of human T cell responses to V160. We demonstrated that V160 de novo induces IE-1 and pp65 specific durable polyfunctional effector CD8 T cells that are comparable to those induced by natural HCMV infection. We identified a variety of V160-responsive T cell clones which exhibit distinctive "transient" and "durable" expansion kinetics, and revealed a transcriptional signature that marks durable CD8 T cells post-vaccination. Our study enhances the understanding of human T-cell immune responses to V160 vaccination.

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos